School of Medicine


Showing 41-50 of 165 Results

  • Alan Schroeder

    Alan Schroeder

    Clinical Professor, Pediatrics

    BioDr. Schroeder is the associate chief for research in the division of pediatric hospital medicine at Lucile Packard Children’s Hospital Stanford, and a clinical professor in the division of hospital medicine and the division of critical care. His research interests focus on identifying areas where we can “safely do less” in healthcare, striving to ensure that children get the healthcare that they need while avoiding excessive tests and treatments that only cause harm. Dr. Schroeder is currently involved in multiple projects involving common conditions and interventions in pediatrics. He serves as the Stanford PI for PEDSNet and is an Associate Editor for the journal Hospital Pediatrics. At Stanford he co-leads the residency clinical research scholarly concentration and the faculty Clinical Research Peer Scholarship Community. Dr. Schroeder provides clinical care for children in the PICU and the pediatric ward.

  • Liora Schultz

    Liora Schultz

    Clinical Assistant Professor, Pediatrics - Hematology & Oncology

    BioI am currently postdoctoral research fellow pursuing immunotherapy research in the oncology department at Stanford University. My clinical training as a pediatric hematology oncology fellow at Memorial Sloan Kettering Cancer Center highlighted the desperate need for novel therapeutic options for a subtype of aggressive pediatric leukemia, Acute Myeloid Leukemia (AML). Despite our best standard of care for AML, long term survival rates range from 50-60% with an unacceptably high relapse rate of 40%. The urgent need for novel treatments inspired me to pursue a research project in adoptive immunotherapy, genetically modifying Tcells to express artificial T cell receptors, termed chimeric antigen receptors (CARs), that target AML specific antigens. In parallel to my clinical training, I constructed an AML specific CAR and demonstrated its ability to redirect T cell function mediating eradication of AML cells. As the field of CAR therapy rapidly advances, novel methods to optimize this therapeutic modality are imperative. To this end, supported by research demonstrating superior antitumor function of naïve derived effector T cells compared to central memory derived effector T cells, I am investigating whether preferential modification of naïve T cells to express CARs will generate a T cell subpopulation with increased efficacy. Consolidating my clinical and research experiences within highly academic institutes allows me to synthesize my pursuit of scientific rigor and commitment to the field of oncology, with a mission to achieve productive research and translatable results.

  • Jennifer Chie Schymick

    Jennifer Chie Schymick

    Clinical Assistant Professor (Affiliated), Pediatrics - Genetics

    BioPROFESSIONAL EDUCATION

    ∗ Medical Genetics Fellowship Stanford University (2018-2020)
    ∗ General Internal Medicine Residency University of Toronto (2013-2018)
    ∗ M.D. University of California Irvine (2009-2013)
    ∗ Ph.D. Oxford University & National Institutes of Health (2005-2009)
    ∗ B.Sc. Massachusetts Institute of Technology (1998-2002)

  • Christopher Thomas Scott, PhD

    Christopher Thomas Scott, PhD

    Sr Research Scholar, Pediatrics - Center for Biomedical Ethics

    Current Research and Scholarly InterestsMy research focuses on the political, legal, ethical and economic impacts of stem cell research. Topics include: embryonic and adult stem cell research and clinical trials, stem cell banking, human-animal chimeras; cell and gamete donation; international perspectives of bioethics; global economic impacts; national and state regulatory policy, stem cell entrepreneurship, intellectual property and offshore stem cell transplants.